Now Tracking (NYSE American: MAIA) As This Biotech Profile Claims My Watchlist's Top Spot

Attention is being drawn to a significant development...

*Sponsored Now Tracking (NYSE American: MAIA) As This Biotech Profile Claims My Watchlist's Top Spot June 5th Dear Reader, Attention is being drawn to a significant development in the treatment of advanced non-small cell lung cancer. A novel therapeutic approach, recently featured at a leading international oncology conference, has shown promising results in patients unresponsive to current immunotherapies. This innovative method targets telomeres within cancer cells, resulting in substantial tumor regression and heightened immune activity. Clinical findings are attracting recognition from experts and may signal a shift in the management of resistant lung cancer cases. Ongoing clinical trials will further clarify the potential of this therapy, making it an area worth monitoring closely as new data emerges. Another thing to monitor closely? How about a $14 analyst target? From Wednesday's close, this NYSE American profile may be eyeing a healthy 600+% potential upside to that target. Oh. And this isn't the first time I've alerted this profile. When I brought this one to your attention back in 2024, it erupted, running approximately 275+% in a few month span. All of this and more is why this Biotech is topping my watchlist: *MAIA Biotechnology, Inc. (NYSE American: MAIA)* MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Their lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. And based on multiple potential breakout catalysts, MAIA should be considered as watchlist material. Check them out: #1. One Analyst's Target Suggests Over 600% Potential Upside From MAIA's Current Chart Levels. #2. Volatility Could Be In Full Force Based On MAIA's Low Float. #3. A Shareholder Letters Points To The Potential For Key Milestones On The Horizon. #4. MAIA’s THIO Shows Promise For Resistant NSCLC At ASCO 2025. But more on those in a second... MAIA's First-In-Class Cancer Telomere Targeting Agent: THIO THIO (aka 6-thio-dG, 6-thio-2’-deoxyguanosine) is a potentially first-in-class small molecule that is the only direct telomere targeting agent currently in clinical development. Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. THIO’s in vitro activity has been studied in models of several tumor types with active telomerase. A New Therapeutic Strategy THIO is recognized by telomerase and incorporated into telomeres in cancer cells. Once incorporated, THIO compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death. Low doses of THIO, followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models in vivo, and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment. These results demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining their telomere-targeted therapy with immunotherapy (Mender et al., 2020). Clinical Development MAIA is currently advancing THIO in a Phase 2 clinical study in Non-Small Cell Lung Cancer (NSCLC). This is the first study to test THIO’s immune system activation followed by administration of the checkpoint inhibitor cemiplimab, allowing for the immune activation and PD-1 sensitivity to take effect. The trial will test the hypothesis that lower doses of THIO administered prior to Libtayo treatment would enhance and prolong responses in subjects with advanced NSCLC who did not respond or progressed after first-line treatment with a checkpoint inhibitor. Second-Generation Telomere Targeting Agents MAIA has initiated an early-stage research and discovery program aimed at identifying new compounds capable of acting through similar mechanisms of activity as THIO, such as the targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity. The main objective for this program is to discover new compounds with potentially improved specificity towards cancer cells relative to normal cells and with potentially increased anticancer activity. MAIA's Pipeline The company's pipeline includes several targeted immuno-oncology therapies for difficult-to-treat cancers: Grab Sources And More Here: Company Website. Company Presentation. ----- As mentioned above, (NYSE American: MAIA) has several explosive potential catalysts to consider right now. Check these out: #1. One Analyst's Target Suggests Over 600% Potential Upside From MAIA's Current Chart Levels. Back in February, Robert LeBoyer, Senior Vice President and equity research analyst with Noble Life Science Partners, reiterated a $14.00 target on MAIA. From Wednesday's closing valuation, that provides MAIA with upside potential well over 600%! Check out some key report highlights: Phase 3 THIO-104 Confirmatory Trial Is Planned For FY2026. Accelerated Approval requires a Phase 3 confirmatory trial, to be known as THIO-104. This will be a multicenter, open-label trial testing the combination of THIO with a checkpoint inhibitor against a control arm with standard-of-care chemotherapy. Like the Phase 2 trial, it will enroll third-line patients who have progressive disease after at least two courses of chemotherapy, including platinum-based agents, and show resistance to checkpoint inhibitors by SITC criteria. Planned enrollment is for 150 patients in each arm (300 patients total). Conclusion. The design announcement and start of treatment in the final stages of the Phase 2 THIO-101 trial meets our expected timeframe. In December, MAIA and Regeneron amended their agreement to continue the supply of Libtayo through Phase 2 and Phase 3, maintaining the regimen through the NSLC trials. We reiterate our Outperform rating and $14 price target. ----- #2. Volatility Could Be In Full Force Based On MAIA's Low Float. According to info from the Yahoo Finance website, MAIA has a relatively low float. The website reports this profile to have roughly 25.69Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. Could even more positive company news in mid-2025 provide a breakout spark? ----- #3. A Shareholder Letters Points To The Potential For Key Milestones On The Horizon. MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders Lead compound THIO (ateganosine) is the only clinical-stage telomere-targeting anticancer agent throughout the field of cancer discovery Potential FDA filings in 2026 for accelerated approval from THIO-101 and early full approval from THIO-104 ... CHICAGO, April 01, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA" or the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today published a 2025 Shareholder Letter by CEO Vlad Vitoc, M.D. detailing the Company’s key milestones for 2025 including several clinical trials and regulatory pathways. "MAIA continues to bring innovation to the biotech industry as one of the earliest pioneers of telomere targeting as a strategy for cancer treatment. Our lead candidate is THIO (ateganosine), the only clinical-stage telomere-targeting anticancer agent throughout the field of cancer discovery," states Dr. Vitoc at the opening of his shareholder letter. "We are working on multiple potential regulatory pathways that could provide accelerated approval and robust exclusivity for THIO in non-small cell lung cancer (NSCLC). Multiple milestones this year are expected to pave the path toward a potential FDA decision as early as next year." Letter Highlights Phase 2 trial THIO-101 expansion underway; potential filing in 2026 for accelerated approval. Phase 3 THIO-104 set to begin in mid-2025; potential filing in 2026 for early full approval. Lead asset THIO shows exceptional efficacy in advanced NSCLC. Multiple THIO trials planned in additional cancer indications. Significant market opp. in hard-to-treat cancers with unmet medical needs. ... Read the full article here. ----- #4. MAIA’s THIO Shows Promise For Resistant NSCLC At ASCO 2025. MAIA Biotechnology’s Phase 2 THIO-101 trial results were accepted for poster presentation at ASCO 2025, highlighting ateganosine’s (THIO) strong efficacy in third-line, immune checkpoint inhibitor–resistant advanced non-small cell lung cancer (NSCLC). The novel telomere-targeting agent demonstrated significant tumor regression and immune activation, suggesting it could challenge the current NSCLC standard of care and offer hope for hard-to-treat patients. Read the full article here. ----- MAIA Recap - NYSE American Breakout Idea Has 4 Explosive Potential Catalysts #1. One Analyst's Target Suggests Over 600% Potential Upside From MAIA's Current Chart Levels. #2. Volatility Could Be In Full Force Based On MAIA's Low Float. #3. A Shareholder Letters Points To The Potential For Key Milestones On The Horizon. #4. MAIA’s THIO Shows Promise For Resistant NSCLC At ASCO 2025. ----- Coverage is officially reinitiated on (NYSE American: MAIA). When updates are available, I'll get them out quickly. Talk soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 06/05/2025 and ending on 06/05/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid eighty six thousand two hundred fifty USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (MAIA:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/maia-74uud/#details

Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice